Foster & Motley Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,566 shares of the company’s stock after buying an additional 996 shares during the period. Johnson & Johnson comprises about 1.3% of Foster & Motley Inc.’s investment portfolio, making the stock its 22nd largest position. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $7,744,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Nwam LLC increased its stake in Johnson & Johnson by 35.6% during the first quarter. Nwam LLC now owns 15,406 shares of the company’s stock valued at $1,919,000 after purchasing an additional 4,042 shares during the last quarter. Searle & CO. increased its stake in Johnson & Johnson by 11.0% during the first quarter. Searle & CO. now owns 40,304 shares of the company’s stock valued at $5,020,000 after purchasing an additional 4,000 shares during the last quarter. Strategic Financial Group LLC increased its stake in Johnson & Johnson by 8.4% during the first quarter. Strategic Financial Group LLC now owns 4,425 shares of the company’s stock valued at $551,000 after purchasing an additional 344 shares during the last quarter. Pillar Pacific Capital Management LLC increased its stake in Johnson & Johnson by 4.7% during the first quarter. Pillar Pacific Capital Management LLC now owns 50,577 shares of the company’s stock valued at $6,299,000 after purchasing an additional 2,290 shares during the last quarter. Finally, Alpha Cubed Investments LLC increased its stake in Johnson & Johnson by 17.2% during the first quarter. Alpha Cubed Investments LLC now owns 91,698 shares of the company’s stock valued at $11,421,000 after purchasing an additional 13,455 shares during the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

JNJ has been the subject of several recent research reports. Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. UBS Group reissued a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Thursday, August 31st. Cowen set a $147.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, October 6th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $145.47.

Johnson & Johnson (NYSE:JNJ) opened at $140.09 on Wednesday. The stock has a market cap of $376,350.00, a price-to-earnings ratio of 24.32, a PEG ratio of 2.85 and a beta of 0.80. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.68 earnings per share. sell-side analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.40%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/12/27/johnson-johnson-jnj-shares-bought-by-foster-motley-inc.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.